Targeting BRAF V600E in metastatic colorectal cancer

BRAF mutations as a therapeutic target in metastatic colorectal ...

BRAF V600E mutation, which is by far the most common (80–97%) among BRAF mutations in CRC patients, results in substitution of glutamic acid (E) for valine (V) ...

Treatment Options for BRAF V600E–Mutant Metastatic Colorectal ...

It doesn't work well as a single agent in colorectal cancer vs other cancers. We have to combine it with anti-EGFR therapy, and encorafenib is ...

Exploring the best treatment options for BRAF-mutant metastatic ...

The BRAFV600E mutation is a well-accepted poor prognostic factor in patients with metastatic colorectal cancer (mCRC), as it confers ...

Triplet-targeted therapy improves survival for patients with advanced ...

BRAF mutations are estimated to occur in up to 15% of patients with mCRC, with V600E being the most common BRAF mutation and representing a poor ...

Plasmatic BRAF-V600E allele fraction as a prognostic factor in ...

... V600EBRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study ... metastatic colorectal cancer (mCRC) treated with doublet or triplet targeted therapy.

The Evolutionary Landscape of Treatment for BRAF V600E Mutant ...

The BRAFV600E mutation is found in 8–10% of metastatic colorectal cancer (mCRC) patients and it is recognized as a poor prognostic factor with a median ...

Phase IB Study of Vemurafenib in Combination with Irinotecan and ...

In vitro, EGFR inhibition, combined with the BRAF inhibitor vemurafenib, causes synergistic cytotoxicity for BRAFV600E metastatic colorectal cancer, ...

Glimmers of Hope—New Strategies for Overcoming Treatment ...

BRAF V600E-mutated metastatic colorectal cancer is notoriously difficult to treat due to an aggressive tumor biology and resistance to chemotherapy.

BRAF, MEK and EGFR inhibition as treatment strategies in BRAF ...

Clinical outcomes and G3/4 adverse e vents of targeted therapies in. BRAF. V600E mutant colorectal cancer. ... previously untreated BRAF V600E-mutant metastatic ...

Immunotherapy Combined With Targeted Therapy in Patients With ...

In one of the first clinical trials combining immunotherapy and targeted therapy for patients with BRAF V600E–mutated colorectal cancer, ...

Treatment Options in BRAF-mutant Metastatic Colorectal Cancer

Recently, the development of BRAF V600E inhibitors has expanded the therapeutic armamentarium, although exclusive targeting of BRAF has proved ...

Targeting BRAF V600E in metastatic colorectal cancer - YouTube

Dr Rodrigo Motta Guerrero discusses his ecancermedicalscience journal article 'Targeting BRAF V600E in metastatic colorectal cancer: where ...

BRAF V600E Metastatic Colorectal Cancer: Perspective from a ...

Around 8–12% of patients with metastatic colorectal cancer will present with a BRAF mutation in their tumour, the majority of which are V600E, ...

(PDF) Targeting BRAF V600E in metastatic colorectal cancer

PURPOSE BRAF V600E mutations are rarely associated with objective responses to the BRAF inhibitor vemurafenib in patients with metastatic colorectal cancer (CRC) ...

BRAF V600E and metastatic colorectal cancer

An article from the oncology section of Primary Care Notebook: BRAF V600E and metastatic colorectal cancer ... targeting BRAF + MEK +EGFR hold ...

Prognostic factors of BRAF V600E colorectal cancer with liver ...

BRAF V600E-mutant colorectal cancers (CRCs) are associated with shorter survival than BRAF wild-type tumors. Therapeutic decision-making for ...

Durable Remission After Targeted Therapy in BRAF V600E–Mutant ...

We report a case of a patient with metastatic-deficient mismatch repair, BRAF V600E–mutated CRC, who achieved a durable complete response to vemurafenib plus ...

BRAF-Targeted Therapy for BRAF V600E-Mutant Metastatic ...

BRAF V600E mutation in metastatic colorectal cancer (CRC) is a poor prognostic factor that leads to resistance to EGFR-targeted therapy. Recent ...

BRAF-Mutated Colorectal Cancer: Early Frustrations and ... - OncLive

The V600E BRAF mutation occurs in 5% to 15% of colorectal cancer patients and is a negative prognostic feature. BRAF-directed therapies in ...

BRAF-Mutant Colorectal Cancer: Latest Findings for Targeted ...

ANCHOR CRC enrolled patients with BRAF V600E mutations previously untreated for metastatic disease. Dr. Van Cutsem presented the main analysis ...